Farmers & Merchants Investments Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 144,326 shares of the company’s stock after selling 2,141 shares during the period. Johnson & Johnson makes up 1.5% of Farmers & Merchants Investments Inc.’s investment portfolio, making the stock its 11th biggest holding. Farmers & Merchants Investments Inc.’s holdings in Johnson & Johnson were worth $20,165,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. BlackRock Inc. lifted its position in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC lifted its position in Johnson & Johnson by 717.9% during the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after acquiring an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. lifted its position in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in Johnson & Johnson by 47.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in Johnson & Johnson by 6,715.9% during the 3rd quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock worth $334,777,000 after acquiring an additional 2,534,918 shares during the last quarter. Hedge funds and other institutional investors own 67.23% of the company’s stock.
NYSE:JNJ opened at $126.66 on Monday. Johnson & Johnson has a 12-month low of $121.54 and a 12-month high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The stock has a market capitalization of $339,816.38, a P/E ratio of 17.35, a price-to-earnings-growth ratio of 1.96 and a beta of 0.74.
A number of research firms have weighed in on JNJ. Wells Fargo reissued an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research report on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Finally, BTIG Research reissued a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $142.83.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.22% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Week Herald and is the property of of Week Herald. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://weekherald.com/2018/04/23/johnson-johnson-jnj-shares-sold-by-farmers-merchants-investments-inc.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.